On April 5, 2023 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023 (Press release, CytoDyn, APR 5, 2023, View Source [SID1234629831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.

Date: Tuesday, April 11, 2023
Time: 1:00 pm PT / 4:00 pm ET
Access: View Source
Questions: Please submit any questions prior to the webcast, and not later than Noon PT, Friday, April 7, 2023. Questions can be submitted via email to: [email protected]. Per CytoDyn’s current policy, the presenters will not be able to take live questions during the webcast.
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until May 11, 2023.